CPC A61K 31/05 (2013.01) [A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01)] | 18 Claims |
1. A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-IV, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of: (i) qualitative impairment in social interaction; (ii) qualitative impairment in communication; and (iii) restricted repetitive and stereotyped patterns of behaviour interest and activities.
|